We use cookies to enhance your experience. By continuing to browse this site you agree to our use of cookies. More info.

The blood-brain barrier (BBB) prevents the passage of foreign substances from the blood to the brain's extracellular fluid. Several drugs that permeate through the BBB are compromised, and only an insufficient amount reaches the targeted tissues. Nanoparticle-based systems present an excellent opportunity to overcome the challenges associated with drug administration via the intranasal route.

Scientists have recently reviewed research articles related to the application of inorganic nanoparticles in delivering drugs to the brain through the intranasal route. This review is available in Applied Materials Today.

BBB and cerebrospinal fluid separate the central nervous system from systemic blood circulation. It further maintains homeostasis and protects the brain from external injuries. In a healthy person, BBB ensures proper brain functioning by preventing the influence of external blood materials in the brain's extracellular fluid.

BBB comprises a monolayer of tightly connected endothelial capillary cells that permits selective penetration of hormones and nutrition. Additionally, this membrane also resists the entry of toxins, pathogens, and foreign bodies like drugs. BBB impairs the entry of large and low-weight molecules; however, it allows the passage of smaller and highly lipophilic substances.

The compounds present in oral or systemic drugs must first pass through the BBB to reach the CNS. Drugs reach the brain through mechanisms such as passive diffusion and active transport. BBB contains specific transporter proteins and receptors that allow the entry of essential substances, such as insulin receptor, glucose transporter GLUT1, and transferrin receptor TfR. The presence of efflux transporters on the endothelial cells restricts the uptake of several molecules into the brain and forces drugs to re-enter systemic circulation.

For the treatment of CNS disorders (e.g., multiple sclerosis, Alzheimer's disease, Parkinson's disease, neurocysticercosis, and meningitis), optimal drug concentration must reach the brain. CNS disorders are associated with a wide range of pathological symptoms due to impaired neural function and damaged neural structures. Several drugs used for the treatment of CNS disorders are associated with side effects that negatively impact patients' quality of life.

The nasal cavity is divided into three regions, namely, the respiratory region, the vestibular region, and the olfactory region. The Intranasal (IN) route of drug administration is an efficient method to attain high drug levels in the brain. Therefore, it is considered an alternative drug administration route.  

The nasal cavity presents a minimally invasive route for drug delivery with rapid action. The olfactory region of the nasal cavity provides direct access to the brain. Additionally, the IN cavity contains high-density microvasculature, which is associated with drug absorption and distribution.

Drug delivery through the IN route aids in the reduction of systemic side effects. This route also avoids the problems associated with drug degradation in the gastrointestinal tract. The IN route can achieve direct drug delivery through the sensory neuronal pathway or indirect delivery via the passage across the BBB from the systemic circulation.

Some of the challenges associated with nasal-based formulations include small volume formulation that can be introduced to the nose and the presence of a mucus layer and local enzymes that can inactivate drugs or minimize their absorption. The nasal mucosal layer, coupled with ciliary movement, can limit the retention time of the drug dosage and resist the movement of drug molecules towards the CNS.  

Nanoparticle-based drug delivery systems have proved to be promising tools to deliver and accumulate therapeutic agents in the CNS by enhancing the permeability across the olfactory region. Their unique characteristic size and functions, such as reactivity, strength, surface area, and solubility, aid in crossing the BBB.

The key factor that must be controlled in IN formulations is the size of nanoparticle-based systems because it impacts the drug loading, release, stability, and targeting towards the CNS. The nanoparticle size also impacts the pharmacokinetics of nanocarriers, including absorption, circulation time, and biodistribution. Small particle size with greater surface area promote enhanced drug solubility, stronger interaction with mucosa, and better permeation than drug solution.

The nanocarrier's surface charge also influences drug performance post IN administration. Positive zeta potentials offer better interaction with the negatively charged mucin residues and favor better retention of the nanoformulations in the nasal mucosa for a longer period. IN-based nanoformulations revealed better drug uptake, permeability, and absorption in the olfactory region and promoted accumulation in the CNS. 

Proteins with receptors in the olfactory region (e.g., lectins) are considered the gold standard for active brain targeting. Hence, incorporating other strategies, such as adding mucoadhesive agents, in nanoparticulate-based systems promotes a higher degree of selective drug delivery to the brain.

Biodegradable and biocompatible polymer nanoparticles, such as poly(caprolactone) (PCL), poly(lactic acid) (PLA), lipid-based nanocarriers, nanovesicular particles, gold nanoparticles, magnetic nanoparticles, and silica nanoparticles, are associated with IN drug delivery to CNS.

Posted in: Medical Science News | Medical Research News

Tags: AIDS, Alzheimer's Disease, Blood, Brain, Central Nervous System, Drug Delivery, Drugs, Gastrointestinal Tract, Glucose, Gold Nanoparticles, Insulin, Membrane, Meningitis, Multiple Sclerosis, Nanoparticle, Nanoparticles, Nervous System, Nutrition, Parkinson's Disease, Particle Size, Pharmacokinetics, Receptor, Research, Respiratory, Sclerosis, Toxins

Priyom holds a Ph.D. in Plant Biology and Biotechnology from the University of Madras, India. She is an active researcher and an experienced science writer. Priyom has also co-authored several original research articles that have been published in reputed peer-reviewed journals. She is also an avid reader and an amateur photographer.

Please use one of the following formats to cite this article in your essay, paper or report:

Bose, Priyom. (2022, September 07). Recent developments in the use of nanoparticles to deliver drugs to the brain via intranasal administration. News-Medical. Retrieved on September 10, 2022 from https://www.news-medical.net/news/20220907/Recent-developments-in-the-use-of-nanoparticles-to-deliver-drugs-to-the-brain-via-intranasal-administration.aspx.

Bose, Priyom. "Recent developments in the use of nanoparticles to deliver drugs to the brain via intranasal administration". News-Medical. 10 September 2022. <https://www.news-medical.net/news/20220907/Recent-developments-in-the-use-of-nanoparticles-to-deliver-drugs-to-the-brain-via-intranasal-administration.aspx>.

Bose, Priyom. "Recent developments in the use of nanoparticles to deliver drugs to the brain via intranasal administration". News-Medical. https://www.news-medical.net/news/20220907/Recent-developments-in-the-use-of-nanoparticles-to-deliver-drugs-to-the-brain-via-intranasal-administration.aspx. (accessed September 10, 2022).

Bose, Priyom. 2022. Recent developments in the use of nanoparticles to deliver drugs to the brain via intranasal administration. News-Medical, viewed 10 September 2022, https://www.news-medical.net/news/20220907/Recent-developments-in-the-use-of-nanoparticles-to-deliver-drugs-to-the-brain-via-intranasal-administration.aspx.

In this interview, News Medical speaks to Jeffrey Stogsdill, Ph.D., about his latest research exploring how microglia change their state to adapt to different areas of the brain.

Until recently, cells were typically counted on a reusable quartz hemocytometer.

In this interview, we speak to Morteza Sarmadi from MIT about his labs latest research that developed microparticles able to deliver self-boosting vaccines.

News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide.

This site complies with the HONcode standard for trustworthy health information: verify here.

News-Medical.net - An AZoNetwork Site

Owned and operated by AZoNetwork, © 2000-2022